Skip to main
INSM

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 39%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc has demonstrated a strong financial outlook, with Brinsupri revenue in Q4 reaching $144.6 million, nearly doubling its previous best quarterly performance, which underscores the robust demand following its U.S. launch and EU approval. This sales momentum reflects a double-digit year-over-year growth trend maintained for seven consecutive years, positioning the company for continued market penetration in treating chronic diseases. Additionally, the positive feedback from healthcare professionals, combined with the potential for significant expansion of its market share, indicates that Insmed is on a trajectory toward achieving cash flow positivity without the need for further capital raising, alleviating concerns of potential dilution for investors.

Bears say

Insmed Inc's financial outlook is cast in a negative light primarily due to the recent failure of brensocatib in the Phase 2b BiRCh study for chronic rhinosinusitis without nasal polyps, which has significantly lowered expectations for upcoming clinical trials and revenue projections. Additionally, potential risks include an anticipated deceleration in Brinsupri's launch, a reset in out-of-pocket costs impacting prescription volumes, and execution hurdles in Phase 3 trials for other pipeline candidates, which could all hinder financial performance moving forward. Moreover, the company's ongoing cash burn of $165-170 million per quarter raises concerns about its sustainability and capacity to fund critical development initiatives without additional financing.

Insmed (INSM) has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 39% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 18 analysts, Insmed (INSM) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $195.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $195.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.